.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cipla
Mallinckrodt
McKinsey
Farmers Insurance
Queensland Health
Fuji
Moodys
Covington
Fish and Richardson

Generated: November 23, 2017

DrugPatentWatch Database Preview

XOFIGO Drug Profile

« Back to Dashboard

Which patents cover Xofigo, and what generic Xofigo alternatives are available?

Xofigo is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-four patent family members in twenty-one countries and eleven supplementary protection certificates in ten countries.

The generic ingredient in XOFIGO is radium ra-223 dichloride. One supplier is listed for this compound. Additional details are available on the radium ra-223 dichloride profile page.

Summary for XOFIGO

US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 16
Drug Prices:see details
DailyMed Link:XOFIGO at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
XOFIGO
radium ra-223 dichloride
SOLUTION;INTRAVENOUS203971-001May 15, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Bayer Hlthcare
XOFIGO
radium ra-223 dichloride
SOLUTION;INTRAVENOUS203971-001May 15, 2013RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: XOFIGO

Country Document Number Estimated Expiration
European Patent Office1140212► Subscribe
Turkey200201442► Subscribe
New Zealand534618► Subscribe
New Zealand513135► Subscribe
Japan4649044► Subscribe
Japan2010168397► Subscribe
China1767078► Subscribe
Japan2002534399► Subscribe
Brazil9916768► Subscribe
Spain2268888► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: XOFIGO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
7Finland► Subscribe
90034-4Sweden► SubscribePRODUCT NAME: RADIUM-223; REG. NO/DATE: EU/1/13/873 20131113
2014000052Germany► SubscribePRODUCT NAME: RADIUM-223-SALZ, INSBESONDERE RADIUM-223-DICHLORID; REGISTRATION NO/DATE: EU/1/13/873 20131113
2014 00027Denmark► SubscribePRODUCT NAME: RADIUM-223 OG OPLOESELIGE SALTE DERAF, HERUNDER RADIUM-223 DICHLORID; REG. NO/DATE: EU/1/13/873 20131113
2014 00027Denmark► SubscribePRODUCT NAME: RADIUM-223 OG OPLOESELIGE SALTE DERAF, HERUNDER RADIUM-223 DICHLORID; REG. NO/DATE: EU/1/13/873 20131113
14/033Ireland► SubscribePRODUCT NAME: RADIUM-223 AND SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/873 20131113
425Luxembourg► SubscribePRODUCT NAME: DICHLORURE DE RADOIM RA 2232 ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES(XOFIGO)
00666Netherlands► SubscribePRODUCT NAME: RADIUM-223, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/13/873/001 20131113
1140212/01Switzerland► SubscribePRODUCT NAME: RADIUM RA-223; REGISTRATION NO/DATE: SWISSMEDIC 62732 29.08.2014
/2014Austria► SubscribePRODUCT NAME: RADIUM-223-DICHLORID; REGISTRATION NO/DATE: EU/1/13/873 20131113
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Teva
Chinese Patent Office
Citi
Express Scripts
Baxter
Cipla
Deloitte
Argus Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot